JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Inclusion Criteria:

• Written informed consent.

• Participant must be ≥18 years of age at the time of signing the Informed ConsentForm (ICF).

• ECOG performance status score of 0 or 1.

• Has been treated with at least one line of systemic therapy for that tumor type andstage.

• Have documentation of confirmed TP53 Y220C mutation.

• At least 1 measurable lesion per RECIST v1.1.

• Adequate hematological, renal and hepatic function and appropriate coagulationcondition.

• Able to swallow and retain orally administered medication.

Exclusion Criteria:

• Active brain or spinal metastases or primary CNS tumor.

• Active infection requiring systemic treatment within 7 days.

• Active HBV or HCV.

• Any severe and/or uncontrolled medical conditions.

• LVEF ≤50% assessed by ECHO or MUGA.

• QTcF>470 msec.